Nivalis Therapeutics to merge with Alpine Immune Sciences

|About: Alpine Immune Sciences, Inc. (ALPN)|By:, SA News Editor

Nivalis Therapeutics (NASDAQ:NVLS+26.9% AH after disclosing it will merge with Alpine Immune Sciences in an all-stock deal.

Alpine will take over what is essentially a non-operating NVLS shell company following the January failure of a cystic fibrosis drug clinical trial; once the merger is complete in Q3, the combined companies will take the Alpine Immune Sciences name and focus on its pipeline of protein-based immunotherapy drugs.

Alpine's public market debut marks a return of controversial former Dendreon CEO Mitch Gold.

Subscribe for full text news in your inbox